[
  {
    "ts": null,
    "headline": "INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream",
    "summary": "Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.",
    "url": "https://finnhub.io/api/news?id=5197adc110d62335c30c919cb7fdefab717173c8d1e57312bbe6828b24a6a3cd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758293580,
      "headline": "INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream",
      "id": 136820110,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.",
      "url": "https://finnhub.io/api/news?id=5197adc110d62335c30c919cb7fdefab717173c8d1e57312bbe6828b24a6a3cd"
    }
  },
  {
    "ts": null,
    "headline": "3 Potential Biotech Acquisition Targets",
    "summary": "These three promising biotech stocks are poised for growth or potential buyouts. Here's what investors need to know.",
    "url": "https://finnhub.io/api/news?id=d9a798f8ba685bf861c9a4c441f91b9671bd789ecad853c9cdb2813d12ae50b1",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758286433,
      "headline": "3 Potential Biotech Acquisition Targets",
      "id": 136820437,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2123099456/image_2123099456.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "These three promising biotech stocks are poised for growth or potential buyouts. Here's what investors need to know.",
      "url": "https://finnhub.io/api/news?id=d9a798f8ba685bf861c9a4c441f91b9671bd789ecad853c9cdb2813d12ae50b1"
    }
  }
]